Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature

Giannone, Gaia; Scotto, Giulia; Katsaros, Dionyssios; Giorgi, Ugo De; Farolfi, Alberto; Borella, Fulvio; Cosma, Stefano; Ferrero, Annamaria; Mangiacotti, S.; Villa, Michela; Tuninetti, Valentina; Ghisoni, Eleonora; Turinetto, Margherita; Mittica, Gloria; Gemmiti, Silvia; Zavallone, Laura; Pasini, Barbara; Maïo, Massimo Di; Valabrega, Giorgio

doi:10.1016/j.ygyno.2021.04.018

Cited by 6 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rolfe et al ( 8 ) studied the relationship between BRCA mutation status and the risk of carboplatin-related allergic reactions and found that pathogenic BRCA variants did not increase the risk of carboplatin allergy in patients with ovarian cancer. However, Giannone ( 9 ) et al systematically evaluated the relationship between pathogenic BRCA variants and the risk of carboplatin-related allergic reactions, reviewing a total of 5 studies including 432 patients with ovarian cancer, and found that pathogenic BRCA variants significantly increased carboplatin allergy risk in patients with ovarian cancer. The results of our study demonstrate that the occurrence of carboplatin allergic reactions during chemotherapy in ovarian cancer patients with pathogenic BRCA variants was substantially increased; however, the multivariate COX analysis did not show statistical significance.…”

Section: Discussionmentioning

confidence: 99%

“…It has rarely been described whether the BRCA mutation status affects the risk of adverse reactions caused by chemotherapy in ovarian cancer patients, and the conclusions are inconsistent. Kotsopoulos et al ( 7 ) reported that BRCA variants do not increase the risk of hematological adverse reactions caused by chemotherapy in patients with ovarian cancer; Rolfe et al ( 8 ) reported that BRCA variants do not increase the risk of allergic reactions to carboplatin; whereas, Giannone et al ( 9 ) found that the allergic reactions to carboplatin in patients with BRCA mutations are significantly increased during chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study

Zeng

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo study the correlation between BRCA mutation status and the risk of adverse reactions in patients with ovarian cancer.MethodA real-world study was conducted at the largest gynecological oncology center in western China, the West China Second University Hospital of Sichuan University. The research subjects were patients diagnosed with ovarian cancer who were initially treated in our hospital from January 2016 to January 2020 and had their BRCA gene status evaluated. Multivariate Cox analysis was conducted to investigate the correlation between the BRCA mutation status and adverse reactions in ovarian cancer patients during initial treatment.ResultsA total of 349 ovarian cancer patients were enrolled, including 79 patients with pathogenic BRCA variants, resulting in a pathogenic mutation rate of 22.6%. Among these 79 patients, 57 had BRCA1 variants and 22 had BRCA2 variants, yielding a pathogenic mutation rate of 16.3% and 6.3%, respectively. Multivariate COX analysis revealed that pathogenic BRCA variants were not related to the risk of adverse reactions, such as myelosuppression and allergies to chemotherapy drugs (P>0.05), during the initial treatment of ovarian cancer.ConclusionBRCA variants did not increase the risk of adverse reactions, such as myelosuppression and allergies to chemotherapy drugs, in ovarian cancer patients during initial treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study

Zeng

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Platinum salts create DNA interstrand crosslinks that are extremely difficult to cleave in the absence of homologous recombination (HR), which leads to the death of HR-deficient (HRD) cancer cells [129]. Augmented sensitivity of BRCA1/2 mutated cancers to platinum salts has been well documented in numerous studies, for instance in those on ovarian cancer [130], pancreatic cancer [131], breast cancer [132]. If the normal copy of BRCA1 or BRCA2 is retained, the efficacy of platinum based therapies is decreased [133].…”

Section: Platinum Complexesmentioning

confidence: 99%

BRCA Mutations: The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers

Loboda¹,

Adonin²,

Zvereva³

et al. 2023

Preprint

View full text Add to dashboard Cite

Two related tumor suppressor genes, Brca1 and Brca2, attract a lot of attention from both fundamental and clinical points of view. Oncogenic hereditary mutations in these genes are firmly linked to the early onset of breast and ovarian cancers. However, the molecular mechanisms that drive extensive mutagenesis in these genes are not known. In this review we hypothesize that one of the potential mechanisms behind this phenomenon can be mediated by Alu mobile genomic elements. Linking mutations in the BRCA1 and BRCA2 genes to the general mechanism(s) of genome stability and DNA repair is critical to ensure the rationalized choice of anti-cancer therapy. Accordingly, we review the literature available on mechanisms of DNA damage repair where these proteins are involved in and how the inactivating mutations in these genes (BRCAness) can be exploited in anti-cancer therapy. We also propose a hypothesis that explains why breast and ovarian epithelial tissues are preferentially susceptible to mutations in BRCA genes. Finally, we discuss perspectives of novel therapeutic approaches for treating BRCAness cancers.

show abstract

Carboplatin

2021

Reactions Weekly

View full text Add to dashboard Cite

Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature

Cited by 6 publications

References 39 publications

BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study

BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study

BRCA Mutations: The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers

Carboplatin

Contact Info

Product

Resources

About